The launch of SelexION Technology on the TripleTOF® 5600+ System provides more confident identification and quantitation of molecules by delivering an additional level of separation between the liquid chromatography (LC) system and the mass spectrometer. This separation can be applied at the molecular level, the biological sub-class level or for the general removal of background interferences. The addition of SelexION Technology on this high-performing accurate mass-based system with high sensitivity and high resolution extends mass spectrometry performance with differential ion mobility, which enables a new dimension of separation and selectivity.
SCIEX also introduced at ASMS new enhancements to two critical tools in proteomics workflows, including SWATH® Acquisition, a technique that enables researchers to reproducibly quantify all detectable components in a single injection. Next-generation SWATH® Acquisition improves data scoring, filtering and support for variable window acquisition, up to 5x speed and scale improvement and enhanced tools for visualization and transfer of complex data sets. Also introduced today was a new version of ProteinPilot Software, which improves identification and quantitative results faster on larger data sets.
“We continue to evolve our innovations to broaden their usefulness with additional features and functionality that provide greater confidence in results,” said Dave Hicks, Vice President and General Manager of the Pharma and Academic Business at SCIEX. “The development of these expanded versions of SWATH® and SelexION are the direct result of feedback we received from customers who saw the potential to apply these breakthrough technologies to a wider range of analytical challenges.”
Several of the speakers at the SCIEX Users meeting yesterday shared about their experiences with SWATH® Acquisition, SelexION Technology and ProteinPilot software as well as the TripleTOF accurate mass-based platform. An increasing number of researchers are taking full advantage of the speed, precision and integration of qualitative and quantitative capabilities of SCIEX instrumentation to generate valuable data.
Researchers using SCIEX technologies are, for example, accelerating the understanding of the molecular basis of diseases. Others are in the process of scaling up the steps to validate biomarker candidates, with the ultimate goal to potentially bring those markers into the clinic.
Among the 30 speakers at the SCIEX Users Meeting were: Ruedi Aebersold (ETH Zurich);Jenny Van Eyk (Johns Hopkins University); Jeffrey Whiteaker (Fred Hutchinson Cancer Research Center); Paul Moench (Novartis); Brendon Kapinos (Pfizer); Mingshe Zhu (Bristol Myers Squibb); Todd Mitchell (University of Wollongong), among others.
Throughout the week at the ASMS conference, SCIEX will continue showcasing customer success utilizing its innovative platforms. In addition, scientists from the company will be demonstrating ways to accelerate and improve workflows on a variety of instruments, including the SCIEX 6500 series, SCIEX 4500 series, TripleTOF 5600+ System, TripleTOF 4600 System, Eksigent NanoLC™ / cHiPLC® system and Eksigent ekspert™ microLC system.
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to push the limits in their field and address the complex analytical challenges they face. The company's global leadership and world-class service and support in the mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With 30 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. Follow SCIEX on Twitter @ABSCIEX and on Facebook and LinkedIn.